Early Access Program

Expedite Your Therapeutic Pipeline with Early Access to Innovative Cell Lines and Ready-to-use Assays

In the fast-paced world of drug discovery, gaining an advantage is essential. With Eurofins DiscoverX's Early Access Program, you gain primary access to next-generation assay technologies and tools designed to fast-track your development pipeline and give you a decisive edge.

Be the first to obtain and implement cutting-edge assays still in development, enabling you to evaluate novel technologies for biologics and small-molecule therapeutics months before their official release.

Lead innovation and accelerate your workflows:

Move Faster: Integrate emerging assays before they reach the broader market
Test Earlier: Explore new formats or targets in your lab ahead of competitors
Innovate Boldly: Work with limited-validation tools designed for an experienced R&D team

The early access program is ideal for biopharma R&D teams, biologics developers, and cell/gene therapy innovators seeking a competitive advantage. The program helps scientific researchers eager to evaluate and shape the latest assay platforms.

Program Highlights

Pre-release Availability – Access cell lines and assays well before public launch and receive early data and protocols to begin internal testing
First-line Technical Support – Obtain expertise to help you implement and optimize early-stage assays
Prioritized Fulfillment – Receive early production batches with prioritized ordering
Valued Contributor - Share feedback that directly influences final assay development

Consider Eurofins DiscoverX’s custom development capabilities for custom cell lines, assays, & enzyme development.

Highlights

Cell Lines

Ready-to-Use Assays

Platforms

Highlights

Advantages of the Early Access Program

Like Eurofins DiscoverX^® catalog products, early access cell lines and assays are built to support critical stages of drug development, including:

Target screening and discovery
Therapeutic candidate characterization
Stability and forced degradation studies
Neutralizing antibody (NAb) detection
Potency assays for lot release

Program Participation Notes

Early Access assays are provided “as-is” and may be further optimized before full catalog release
Participant feedback is highly encouraged to guide future improvements
Technical support is available but may be more limited than for fully released products
Some cell lines and assays have been developed but may lack specific information required for launch compared to a released catalog product. For example, a tool (ligand) molecule may not yet be commercially available to demonstrate a functional response.

We encourage you to subscribe to the Eurofins DiscoverX newsletter for notification of the upcoming or newly launched cell lines and assays, valuable scientific resources, upcoming events, and other insightful information.